ethyl nicotinate + hexyl nicotinate + tetrahydrofurfuryl salicylate: clinical use

Prescribing considerations

• The selected product is listed as discontinued; confirm availability and use product-specific information for alternatives.
• Restrict application to intact skin and avoid sensitive areas, mucosa, occlusion and excessive sunlight.
• Not recommended for children under 12 years.
• Assess warfarin use and pregnancy or breastfeeding before supply.

Contraindications and cautions

• Hypersensitivity to any active ingredient or excipient.
• Known hypersensitivity to aspirin, other salicylates or NSAIDs, particularly when associated with asthma.

Monitoring

• No routine laboratory monitoring is specified.
• Review local tolerability and stop treatment if rash or sensitisation develops.
• Consider possible enhanced anticoagulation with warfarin.

Clinical pharmacology

Ethyl nicotinate and hexyl nicotinate act as topical rubefacients, producing warmth and erythema. Tetrahydrofurfuryl salicylate is used topically for musculoskeletal, peri-articular and soft-tissue symptoms; product-specific pharmacokinetic data are not stated.

Formulation and product differences

• The selected product is a cream for cutaneous use.
• Methylhydroxybenzoate may cause allergic reactions, including delayed reactions.
• Cetostearyl alcohol may cause local reactions such as contact dermatitis.
• The formulation contains perfume.